An Updated View of the Trypanosoma cruzi Life Cycle: Intervention Points for an Effective Treatment

J Martín-Escolano, C Marín, MJ Rosales… - ACS Infectious …, 2022‏ - ACS Publications
Chagas disease (CD) is a parasitic, systemic, chronic, and often fatal illness caused by
infection with the protozoan Trypanosoma cruzi. The World Health Organization classifies …

Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity

B Zingales - Acta tropica, 2018‏ - Elsevier
The genetic diversity of Trypanosoma cruzi, the protozoan agent of Chagas disease, is
widely recognized. At present, T. cruzi is partitioned into seven discrete ty** units (DTUs) …

Chagas' disease

C Bern - New England Journal of Medicine, 2015‏ - Mass Medical Soc
Chagas’ Disease | New England Journal of Medicine Skip to main content The New England
Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology Clinical …

Hit and lead criteria in drug discovery for infectious diseases of the develo** world

K Katsuno, JN Burrows, K Duncan… - Nature Reviews drug …, 2015‏ - nature.com
Reducing the burden of infectious diseases that affect people in the develo** world
requires sustained collaborative drug discovery efforts. The quality of the chemical starting …

[HTML][HTML] Advances in the treatment of Chagas disease: Promising new drugs, plants and targets

P García-Huertas, N Cardona-Castro - Biomedicine & Pharmacotherapy, 2021‏ - Elsevier
Chagas disease, caused by Trypanosoma cruzi, is treated with only two drugs;
benznidazole and nifurtimox. These drugs have some disadvantages, including their …

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and slee** sickness

S Khare, AS Nagle, A Biggart, YH Lai, F Liang… - Nature, 2016‏ - nature.com
Chagas disease, leishmaniasis and slee** sickness affect 20 million people worldwide
and lead to more than 50,000 deaths annually. The diseases are caused by infection with …

Secondary metabolites from endophytic fungi: Production, methods of analysis, and diverse pharmaceutical potential

VK Singh, A Kumar - Symbiosis, 2023‏ - Springer
The synthesis of secondary metabolites is a constantly functioning metabolic pathway in all
living systems. Secondary metabolites can be broken down into numerous classes …

Challenges and recent progress in drug discovery for tropical diseases

M De Rycker, B Baragaña, SL Duce, IH Gilbert - Nature, 2018‏ - nature.com
Infectious tropical diseases have a huge effect in terms of mortality and morbidity, and
impose a heavy economic burden on affected countries. These diseases predominantly …

Between a bug and a hard place: Trypanosoma cruzi genetic diversity and the clinical outcomes of Chagas disease

LA Messenger, MA Miles, C Bern - Expert review of anti-infective …, 2015‏ - Taylor & Francis
Over the last 30 years, concomitant with successful transnational disease control programs
across Latin America, Chagas disease has expanded from a neglected, endemic parasitic …

Clinical and pharmacological profile of benznidazole for treatment of Chagas disease

J Müller Kratz, F Garcia Bournissen… - Expert Review of …, 2018‏ - Taylor & Francis
Introduction: Chagas disease (CD) is one of the most neglected public health problems in
the Americas, where< 1% of the estimated 6 million people with the infection have been …